• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中低收入国家哮喘诊断和管理的临床标准。

Clinical standards for the diagnosis and management of asthma in low- and middle-income countries.

机构信息

Academic Unit of Primary Care, University of Sheffield, Sheffield.

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

出版信息

Int J Tuberc Lung Dis. 2023 Sep 1;27(9):658-667. doi: 10.5588/ijtld.23.0203.

DOI:10.5588/ijtld.23.0203
PMID:37608484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10443788/
Abstract

The aim of these clinical standards is to aid the diagnosis and management of asthma in low-resource settings in low- and middle-income countries (LMICs). A panel of 52 experts in the field of asthma in LMICs participated in a two-stage Delphi process to establish and reach a consensus on the clinical standards. Eighteen clinical standards were defined: Standard 1, Every individual with symptoms and signs compatible with asthma should undergo a clinical assessment; Standard 2, In individuals (>6 years) with a clinical assessment supportive of a diagnosis of asthma, a hand-held spirometry measurement should be used to confirm variable expiratory airflow limitation by demonstrating an acute response to a bronchodilator; Standard 3, Pre- and post-bronchodilator spirometry should be performed in individuals (>6 years) to support diagnosis before treatment is commenced if there is diagnostic uncertainty; Standard 4, Individuals with an acute exacerbation of asthma and clinical signs of hypoxaemia or increased work of breathing should be given supplementary oxygen to maintain saturation at 94-98%; Standard 5, Inhaled short-acting beta-2 agonists (SABAs) should be used as an emergency reliever in individuals with asthma via an appropriate spacer device for metered-dose inhalers; Standard 6, Short-course oral corticosteroids should be administered in appropriate doses to individuals having moderate to severe acute asthma exacerbations (minimum 3-5 days); Standard 7, Individuals having a severe asthma exacerbation should receive emergency care, including oxygen therapy, systemic corticosteroids, inhaled bronchodilators (e.g., salbutamol with or without ipratropium bromide) and a single dose of intravenous magnesium sulphate should be considered; Standard 8, All individuals with asthma should receive education about asthma and a personalised action plan; Standard 9, Inhaled medications (excluding dry-powder devices) should be administered via an appropriate spacer device in both adults and children. Children aged 0-3 years will require the spacer to be coupled to a face mask; Standard 10, Children aged <5 years with asthma should receive a SABA as-needed at step 1 and an inhaled corticosteroid (ICS) to cover periods of wheezing due to respiratory viral infections, and SABA as-needed and daily ICS from step 2 upwards; Standard 11, Children aged 6-11 years with asthma should receive an ICS taken whenever an inhaled SABA is used; Standard 12, All adolescents aged 12-18 years and adults with asthma should receive a combination inhaler (ICS and rapid onset of action long-acting beta-agonist [LABA] such as budesonide-formoterol), where available, to be used either as-needed (for mild asthma) or as both maintenance and reliever therapy, for moderate to severe asthma; Standard 13, Inhaled SABA alone for the management of patients aged >12 years is not recommended as it is associated with increased risk of morbidity and mortality. It should only be used where there is no access to ICS.The following standards (14-18) are for settings where there is no access to inhaled medicines. Standard 14, Patients without access to corticosteroids should be provided with a single short course of emergency oral prednisolone; Standard 15, Oral SABA for symptomatic relief should be used only if no inhaled SABA is available. Adjust to the individual's lowest beneficial dose to minimise adverse effects; Standard 16, Oral leukotriene receptor antagonists (LTRA) can be used as a preventive medication and is preferable to the use of long-term oral systemic corticosteroids; Standard 17, In exceptional circumstances, when there is a high risk of mortality from exacerbations, low-dose oral prednisolone daily or on alternate days may be considered on a case-by-case basis; Standard 18. Oral theophylline should be restricted for use in situations where it is the only bronchodilator treatment option available. These first consensus-based clinical standards for asthma management in LMICs are intended to help clinicians provide the most effective care for people in resource-limited settings.

摘要

这些临床标准旨在帮助中低收入国家(LMICs)资源有限环境下的医生诊断和管理哮喘。一个由 52 名哮喘领域专家组成的小组参与了两阶段 Delphi 流程,以建立和达成临床标准的共识。定义了 18 项临床标准:标准 1,对于有与哮喘相符的症状和体征的个体,应进行临床评估;标准 2,对于临床评估支持哮喘诊断的个体(年龄>6 岁),应使用手持式肺活量计测量,以证明急性支气管扩张剂反应来确认可变呼气气流受限;标准 3,如果诊断不确定,在开始治疗前应在个体(年龄>6 岁)中进行支气管扩张剂前后的肺活量测量以支持诊断;标准 4,对于有哮喘急性加重且有低氧血症或呼吸功增加的临床体征的个体,应给予补充氧气以维持饱和度在 94-98%;标准 5,对于有哮喘的个体,应通过合适的计量吸入器喷雾器设备使用短效β-2 激动剂(SABA)作为急救缓解药物;标准 6,对于有中度至重度急性哮喘加重的个体,应给予短程口服皮质激素适当剂量;标准 7,对于有严重哮喘加重的个体,应给予紧急护理,包括氧疗、全身皮质激素、吸入性支气管扩张剂(如沙丁胺醇联合或不联合异丙托溴铵)和考虑单次静脉注射硫酸镁;标准 8,所有有哮喘的个体都应接受哮喘教育和个性化行动计划;标准 9,在成人和儿童中,吸入药物(干粉装置除外)应通过合适的喷雾器设备给药。0-3 岁的儿童将需要将喷雾器与面罩连接;标准 10,年龄<5 岁有哮喘的儿童应在第 1 步按需使用 SABA,在呼吸道病毒感染引起喘息期间应使用吸入皮质激素(ICS),并从第 2 步起按需使用 SABA 和每日 ICS;标准 11,年龄 6-11 岁有哮喘的儿童应在每次使用吸入性 SABA 时使用 ICS;标准 12,所有 12-18 岁的青少年和有哮喘的成年人都应使用组合吸入器(ICS 和快速起效的长效β-激动剂[LABA],如布地奈德-福莫特罗),如有必要,按需使用(用于轻度哮喘)或作为维持和缓解治疗,用于中重度哮喘;标准 13,对于>12 岁的患者,单独使用吸入性 SABA 不推荐用于管理,因为它与更高的发病率和死亡率风险相关。仅在无法获得 ICS 时才应使用;标准 14,对于无法获得皮质激素的患者,应提供单次短期紧急口服泼尼松龙;标准 15,仅在没有吸入性 SABA 时,才应使用口服 SABA 缓解症状。调整至个体最低有效剂量以最大程度减少不良反应;标准 16,口服白三烯受体拮抗剂(LTRA)可作为预防药物,优于长期口服全身皮质激素;标准 17,在特殊情况下,如果有因加重而死亡的高风险,可考虑在个案基础上每日或隔日低剂量口服泼尼松龙;标准 18. 口服茶碱应仅限于唯一的支气管扩张剂治疗选择的情况下使用。这些是中低收入国家哮喘管理的第一个基于共识的临床标准,旨在帮助临床医生为资源有限环境下的患者提供最有效的护理。

相似文献

1
Clinical standards for the diagnosis and management of asthma in low- and middle-income countries.中低收入国家哮喘诊断和管理的临床标准。
Int J Tuberc Lung Dis. 2023 Sep 1;27(9):658-667. doi: 10.5588/ijtld.23.0203.
2
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
3
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南(2024年版)]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
4
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.福莫特罗与布地奈德联合用于成人和儿童慢性哮喘的维持和缓解治疗与联合吸入器维持治疗的对比
Cochrane Database Syst Rev. 2013 Dec 16;2013(12):CD009019. doi: 10.1002/14651858.CD009019.pub2.
5
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.按需使用固定剂量β激动剂和类固醇吸入剂治疗轻度哮喘的成人或儿童。
Cochrane Database Syst Rev. 2021 May 4;5(5):CD013518. doi: 10.1002/14651858.CD013518.pub2.
6
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children.福莫特罗与布地奈德联合用于成人和儿童慢性哮喘的维持和缓解治疗与当前最佳实践(包括吸入性糖皮质激素维持治疗)的对比研究
Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD007313. doi: 10.1002/14651858.CD007313.pub3.
7
As-needed ICS-LABA in Mild Asthma: What Does the Evidence Say?按需使用 ICS-LABA 治疗轻度哮喘:证据说了什么?
Drugs. 2019 Nov;79(16):1729-1737. doi: 10.1007/s40265-019-01202-0.
8
Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.布地奈德/福莫特罗维持和缓解治疗在亚洲哮喘患者(≥16 岁)中的应用:COSMOS 研究的一项亚分析。
Clin Drug Investig. 2012 Jul 1;32(7):439-49. doi: 10.2165/11598840-000000000-00000.
9
Regular versus as-needed treatments for mild asthma in children, adolescents, and adults: a systematic review and network meta-analysis.儿童、青少年和成人轻度哮喘的常规治疗与按需治疗:一项系统评价和网状Meta分析
BMC Med. 2025 Jan 21;23(1):21. doi: 10.1186/s12916-025-03847-z.
10
Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.布地奈德福莫特罗缓解治疗与布地奈德加特布他林维持缓解治疗轻中度哮喘成人患者(PRACTICAL):一项 52 周、开放标签、多中心、优效性、随机对照试验。
Lancet. 2019 Sep 14;394(10202):919-928. doi: 10.1016/S0140-6736(19)31948-8. Epub 2019 Aug 23.

引用本文的文献

1
Assessing spirometry, exhaled nitric oxide, and asthma symptoms score as instruments for respiratory health evaluation among women in a low socioeconomic context: a cross-sectional study.评估肺量计、呼出一氧化氮和哮喘症状评分作为低社会经济背景下女性呼吸健康评估工具的研究:一项横断面研究
BMC Public Health. 2025 Jun 5;25(1):2095. doi: 10.1186/s12889-025-23324-9.
2
A year in review - evaluating the launch of IJTLD OPEN.年度回顾——评估《国际结核病与肺部疾病杂志·开放版》的创刊
IJTLD Open. 2025 Jan 1;2(1):1-2. doi: 10.5588/ijtldopen.24.0613. eCollection 2025 Jan.
3
Beliefs surrounding the use of inhaled asthma medication in The Gambia: a qualitative study of asthma patients and healthcare workers.冈比亚哮喘患者和医护人员对吸入性哮喘药物使用的信念:一项定性研究。
NPJ Prim Care Respir Med. 2024 Oct 17;34(1):29. doi: 10.1038/s41533-024-00390-x.
4
A study on physicians' knowledge and practices of asthma management in Angola.安哥拉医生对哮喘管理的知识与实践研究。
Multidiscip Respir Med. 2024 Sep 13;19(1):968. doi: 10.5826/mrm.2024.968.
5
Causes, outcomes and diagnosis of acute breathlessness hospital admissions in Malawi: protocol for a multicentre prospective cohort study.马拉维急性呼吸急促住院患者的病因、结局及诊断:一项多中心前瞻性队列研究方案
Wellcome Open Res. 2024 Apr 17;9:205. doi: 10.12688/wellcomeopenres.21041.1. eCollection 2024.
6
Standards for clinical trials for treating TB.治疗结核病的临床试验标准。
Int J Tuberc Lung Dis. 2023 Dec 1;27(12):885-898. doi: 10.5588/ijtld.23.0341.

本文引用的文献

1
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update.2022 年全球哮喘倡议(GINA)更新:初级保健的主要建议。
NPJ Prim Care Respir Med. 2023 Feb 8;33(1):7. doi: 10.1038/s41533-023-00330-1.
2
Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study.25 个国家儿童、青少年和成人的哮喘管理和控制:全球哮喘网络第一阶段横断面研究。
Lancet Glob Health. 2023 Feb;11(2):e218-e228. doi: 10.1016/S2214-109X(22)00506-X.
3
Key messages and partnerships to raise awareness and improve outcomes for people with asthma and COPD in low- and middle-income countries.提高低收入和中等收入国家哮喘和慢性阻塞性肺疾病患者的认识并改善其治疗效果的关键信息及伙伴关系。
Int J Tuberc Lung Dis. 2022 Dec 1;26(12):1106-1108. doi: 10.5588/ijtld.22.0544.
4
The Global Asthma Report 2022.《2022年全球哮喘报告》
Int J Tuberc Lung Dis. 2022 Nov 25;26(Supp 1):1-104. doi: 10.5588/ijtld.22.1010.
5
Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries.改善中低收入国家获得负担得起的、有质量保证的吸入性药物的途径。
Int J Tuberc Lung Dis. 2022 Nov 1;26(11):1023-1032. doi: 10.5588/ijtld.22.0270.
6
The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review.中低收入国家哮喘和 COPD 基本药物的可及性、成本和可负担性:系统评价。
Lancet Glob Health. 2022 Oct;10(10):e1423-e1442. doi: 10.1016/S2214-109X(22)00330-8.
7
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.沙美特罗替卡松干粉吸入剂(舒利迭)治疗哮喘。
N Engl J Med. 2022 Jun 2;386(22):2071-2083. doi: 10.1056/NEJMoa2203163. Epub 2022 May 15.
8
Asthma management in low and middle income countries: case for change.低收入和中等收入国家的哮喘管理:变革的理由。
Eur Respir J. 2022 Sep 15;60(3). doi: 10.1183/13993003.03179-2021. Print 2022 Sep.
9
The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study.17 个国家成年人哮喘、花粉热和湿疹负担:GAN 阶段 I 研究。
Eur Respir J. 2022 Sep 15;60(3). doi: 10.1183/13993003.02865-2021. Print 2022 Sep.
10
European Respiratory Society guidelines for the diagnosis of asthma in adults.欧洲呼吸学会成人哮喘诊断指南。
Eur Respir J. 2022 Sep 7;60(3). doi: 10.1183/13993003.01585-2021. Print 2022 Sep.